Provexis plc, the life-science business and functional food and sports nutrition specialist that owns Science in Sport (SiS), has confirmed the appointment of John Clarke, the highly experienced former GlaxoSmithKline (GSK) senior executive, as a Non-Executive Director.
Clarke has extensive experience of the functional food and sports nutrition sectors, having worked at GSK for more than 35 years. In 2006 he was appointed global President of GSK Consumer Healthcare, a position from which he recently stepped down. Under his leadership, GSK Consumer Healthcare was reportedly the fastest-growing business in the industry throughout the period, growing by 60% and reaching sales of £5 billion despite a recessionary backdrop in the majority of its business’ markets.
The business added £2 billion in turnover from 2006. During his time at GSK, Clarke was responsible for the Lucozade brand – including strategy, innovation, portfolio and global expansion – for 15 years from 1996 to 2011. Lucozade achieved growth of 13% CAGR through the 1996-2011 period, with sales now approaching £400 million.
Clarke’s appointment at Provexis is effective from 1 April 2012.
Commenting on his new appointment at Provexis, John Clarke said “I am delighted to be joining the Board of Provexis. I believe the recently acquired Science in Sport brand has significant growth potential and I look forward to assisting the company in achieving its true potential. I am particularly impressed by the company’s scientific and regulatory expertise, which has underpinned the development of the Fruitflow heart-health technology, and which will assist also in driving innovation for Science in Sport.”
Dawson Buck, Chairman of Provexis, added “John Clarke is recognised as an outstanding leader in the global consumer healthcare industry and I am therefore delighted that he has decided to join Provexis at this exciting stage in our development. His proven success and in-depth knowledge in the consumer healthcare and sports nutrition sectors will be an important factor as we take Provexis to its next level of development.”
John Milne Clarke, aged 62, holds no shares in Provexis. He was President of GlaxoSmithKline Worldwide Consumer Healthcare, and was a member of GlaxoSmithKline plc Corporate Executive Team until March 2012. Clarke is also the non-executive Chairman of Futura Medical plc.